Highlights of This Issue 2675

SMALL MOLECULE THERAPEUTICS

2677 Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer
Rebecca A. Previs, Guillermo N. Armaiz-Pena, Yvonne C. Lin, Ashley N. Davis, Sunila Pradeep, Heather J. Dalton, Robert L. Coleman, and Anil K. Sood

2678 Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases
Kazuharu Kai, Kimie Kondo, Xiaoping Wang, Xuemei Xie, Mary Kathryn Pitner, Monica E. Reyes, Angie M. Torres-Adorno, Hiroko Masuda, Gabriel N. Hortobagyi, Chandra Bartholomeusz, Hideyuki Saya, Debu Tripathy, Subrata Sen, and Naoto T. Ueno

2680 Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors
Steven R. Whittaker, Glenn S. Cowley, Steve Wagner, Flora Luo, David E. Root, and Levi A. Garraway

2683 Targeting the Neurokinin-1 Receptor Compromises Canonical Wnt Signaling in Hepatoblastoma
Matthias Ilmer, Agnes Garnier, Jody Vykoukal, Eckhard Alt, Dietrich von Schweinitz, Roland Kappler, and Michael Berger

2686 Silibinin Preferentially Radiosensitizes Prostate Cancer by Inhibiting DNA Repair Signaling
Dhanya K. Nambiar, Paulraj Rajamani, Gagan Deep, Anil K. Jain, Rajesh Agarwal, and Rana P. Singh

2693 Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System

LARGE MOLECULE THERAPEUTICS

2744 The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo
Heather Venant, Mehrdad Rahmaniyan, E. Ellen Jones, Ping Lu, Michael B. Lilly, Elizabeth Garrett-Mayer, Richard R. Drake, Jacqueline M. Kraveka, Charles D. Smith, and Christina Voelkel-Johnson

2753 Aurora A Is Critical for Survival in HPV-Transformed Cervical Cancer
Brian Gabrielli, Fawzi Bokhari, Max V. Ranall, Zay Yar Oo, Alexander J. Stevenson, Weiil Wang, Melanie Murrell, Mushfiq Shaikh, Sora Fallaha, Daniel Clarke, Madison Kelly, Karin Sedelies, Melinda Christensen, Sara McKee, Graham Leggatt, Paul Leo, Dubravka Skalamera, H. Peter Soyer, Thomas J. Gonda, and Nigel A.J. McMillan

2762 BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose Homeostasis

2773 MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model
Chandra Bartholomeusz, Xuemei Xie, Mary Kathryn Pitner, Kimie Kondo, Ali Dadbin, Jangsoon Lee, Hitomi Saso, Paul D. Smith, Kevin N. Dalby, and Naoto T. Ueno

2782 High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 Study
Sylvain Manfredi, Olivier Bouché, Philippe Roguier, Laetitia Daham, Marie Anne Loriot, Thomas Aparicio, Pierre Luc Etienne, Jean Pierre Lafargue, Cedric Lécaillé, Jean Louis Legoux, Karine Le Malicot, Emilie Maillard, Thierry Lecomte, Faiza Khemissa, Gilles Breysacher, Pierre Michel, Emmanuel Mitry, and Laurent Bedenne

2789 Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors
Ronit Mazor, Jingli Zhang, Laimin Xiang, Selamawit Addissie, Prince Awuah, Richard Beers, Raffit Hassan, and Ira Pastan
2797  |  Systemic Administration and Targeted Radiosensitization via Chemically Synthetic Aptamer–siRNA Chimeras in Human Tumor Xenografts  
| Xiaohua Ni, Yonggang Zhang, Kenji Zennami, Mark Castanares, Amarnath Mukherjee, Raju R. Raval, Haoming Zhou, Theodore L. DeWeese, and Shawn E. Lupold

COMPANION DIAGNOSTICS AND CANCER BIOMARKERS

2864  |  Genome-Wide Identification of a Methylation Gene Panel as a Prognostic Biomarker in Nasopharyngeal Carcinoma  
| Wei Jiang, Na Liu, Xiao-Zhong Chen, Ying Sun, Bin Li, Xian-Yue Ren, Wei-Feng Qin, Ning Jiang, Ya-Fei Xu, Ying-Qin Li, Jian Ren, William CS Cho, Jing-Ping Yun, Jing Zeng, Li-Zhi Liu, Li Li, Ying Guo, Hai-Qiang Mai, Mu-Sheng Zeng, Tie-Rang Kang, Wei-Hua Jia, Jian-Yong Shao, and Jun Ma

CANCER BIOLOGY AND SIGNAL TRANSDUCTION

2805  |  A TORC2–Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers  
| Dhara N. Amin, Deepika Ahuja, Paul Yaswen, and Mark M. Moasser

2818  |  PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway  
| Florian Engert, Cornelius Schneider, Lilly Magdalena Weiß, Marie Probst, and Simone Fulda

2831  |  ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor  
| Yoshiito Nakanishi, Hideaki Mizuno, Hitoshi Sase, Toshihiko Fujii, Kiyoko Sakata, Nukinori Akiyama, Yuko Aoki, Masahiro Aoki, and Nobuya Ishii

2850  |  Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutilin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model  

MODELS AND TECHNOLOGIES

2901  |  Acute Tumor Lactate Perturbations as a Biomarker of Genotoxic Stress: Development of a Biochemical Model  
| Vlad C. Sandulache, Yunyun Chen, Heath D. Skinner, Tongtong Lu, Lei Feng, Laurence E. Court, Jeffrey N. Myers, Raymond E. Meyn, Clifton D. Fuller, James A. Bankson, and Stephen Y. Lai

2909  |  Acknowledgment to Reviewers
ABOUT THE COVER

The cover image shows the structural model of LMb-T20, a highly potent recombinant immunotoxin consisting of an antimesothelin Fv fused to a portion of Pseudomonas exotoxin A. The toxin has a deletion of domain II and six point mutations in domain III that delete or greatly suppress the eight T-cell epitopes. For details, see the article by Mazor and colleagues on page 2789.
Molecular Cancer Therapeutics

14 (12)

Mol Cancer Ther 2015;14:2675-2912.

Updated version
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/14/12

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.